This study aims to provide real-world information about the duration, safety, and overall benefit of DaxibotulinumtoxinA (also called DAXI) treatment for adults living with blepharospasm (BSP), a condition that causes uncontrolled blinking or muscle spasms around the eyes, which can interfere with vision and daily activities. Specifically, it is being done to learn more about how well and how long DAXI works for treating adults with blepharospasm.
This is a single-center, open-label, single-arm study, meaning everyone in the study will receive DAXI, and both participants and researchers will know what treatment is being given. The study will include 20 adult participants.
Participants may receive two to three treatment cycles of DAXI injections over about 12 months. The timing between treatments will depend on how long each injection works for each person. Injections will be given at least every 90 days (3 months) but no later than every 180 days (6 months). Participants and their doctors will decide when another injection is needed based on symptom control using a tool called the Blepharospasm Severity Tracker Form (BSTF). To make the injections more comfortable, participants may use topical lidocaine cream, cooling spray, or another local anesthetic before injection.
DAXI will be prepared by the injecting clinician or trained staff right before use. The medication is made by mixing a measured amount of DAXI powder with a small amount of sterile saline solution (salt water) to reach the correct concentration. The exact injection technique (including the dose, location, and number of injection sites) will be chosen by the injector based on each participant's needs, but treatment will only be given in specific facial muscles (corrugator, procerus, orbicularis oculi, and nasalis). The use of imaging tools such as electromyography (EMG) or ultrasound is optional and typically not required for injections around the eyes.
The starting DAXI dose will be based on each participant's current or previous botulinum toxin treatment:
* If the participant was previously treated with onabotulinumtoxinA (Botox®), the same number of "units" will be used for DAXI (a 1:1 conversion).
* If the participant was previously treated with incobotulinumtoxinA (Xeomin®), the DAXI dose will be adjusted to about two-thirds of the previous incobotulinumtoxinA dose (a 1.5:1 conversion).
If a participant experienced side effects such as droopy eyelids (ptosis), double vision (diplopia), or dry eyes with prior treatments, that information will help guide dosing decisions. For later injection cycles, the injector may adjust the dose or injection pattern based on how well the participant responds. Whenever possible, the same injector will perform all of a participant's treatments to keep results consistent.
Participants will come to the clinic for in-person visits for most study assessments. After each DAXI injection, the peak effect (best response) will be evaluated about one month later, guided by the BSTF. These visits may be done remotely (via phone or video) when appropriate. The same schedule will be followed for future cycles. For the final treatment, this one-month check will occur unless the participant reports that the treatment's full effect happened sooner.
The main goal (primary endpoint) of the study is to measure how long DAXI's effects last, specifically by tracking the median time until the next injection is needed.
Other key goals (secondary endpoints) include:
* How long participants feel the treatment works
* How severe their blepharospasm symptoms are over time
* What side effects or safety concerns occur (adverse events)

Start Date01 Oct 2026

Sponsor / Collaborator

University of Pennsylvania

[+1]

NCT06195241

/ RecruitingPhase 4IIT

The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

Start Date11 Feb 2025

Sponsor / Collaborator

Montefiore Medical Center

[+1]

NCT06411002

/ CompletedPhase 2

A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines

This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent.
The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

Start Date08 Apr 2024

Sponsor / Collaborator

Revance Therapeutics, Inc.

100 Clinical Results associated with Daxibotulinumtoixn A-LANM

100 Translational Medicine associated with Daxibotulinumtoixn A-LANM

100 Patents (Medical) associated with Daxibotulinumtoixn A-LANM

Literatures (Medical) associated with Daxibotulinumtoixn A-LANM

01 Sep 2026·ANAEROBE

Molecular epidemiology of Clostridioides difficile clinical isolates in a tertiary-care hospital of northern Mexico: single-center real-life study

Article

Author: Camacho-Ortiz, Adrián ; Alcalá-Zúñiga, Daphne ; Domínguez-Rivera, Cristian V ; Bocanegra-Ibarias, Paola ; Salas-Treviño, Daniel ; Flores-Treviño, Samantha

OBJECTIVES:

Currently, Clostridioides difficile infections (CDIs) are one of the leading causes of nosocomial infections worldwide. In Latin America, the most economically developed countries have seen a rise in these infections in recent years, likely driven by expanded hospital capacity and shifting demographic patterns. However, epidemiological data on CDIs in Mexico are scarce. In this study, we evaluated the current molecular epidemiological situation in a tertiary-care hospital in northern Mexico and correlated it with clinical and laboratory data to identify indicators of infection with the hypervirulent RT027 ribotype.

METHODS:

This was a prospective, cross-sectional, analytical, and observational study. Samples were collected from patients with confirmed CDIs using a two-step algorithm. Cultures and molecular analyses were performed for toxigenic classification and ribotyping of the C. difficile strains. Clinical data were also collected to perform correlation analyses with the ribotypes.

RESULTS:

In this study, 71 C difficile strains were collected from 111 samples available for analysis. The genes for toxins A and B were found in 85.9% (61/71) and 81.7% (58/71) of the samples, respectively, while the gene for the binary toxin was detected in 52.1% (37/71) of the samples. RT027 was the most frequently isolated strain (50.7%, 36/71), followed by RT001 (11.3%, 8/71). None of the RTs analyzed showed significant changes over the years of analysis; however, the presence of RT002 and RT014 appeared more frequently in the later years. Patient age was slightly increased in RT027 CDIs, without reaching significance (p = 0.071); days of hospitalization, previous hospitalizations, antibiotic use, ATLAS and Charlson score values showed no differences between RT027 and other ribotypes CDIs.

CONCLUSIONS:

In our study, we observed a moderate predominance of RT027 over the past four years, and the presence of various RTs associated with community-acquired CDIs. Patient age was slightly increased in patients who presented with CDI caused by RT027; however, this data was not statistically significant. More comprehensive studies with larger sample sizes and longer analysis periods are needed to determine the epidemiological shifts in C. difficile ribotypes in Mexico.

01 Jul 2026·Movement Disorders Clinical Practice

Article

Author: Lee, Han S. ; Sparrow, Julia ; Ellenbogen, Aaron ; Bahroo, Laxman ; Patel, Atul T. ; Kazerooni, Rashid ; McAllister, Peter ; Gross, Todd M. ; Gallagher, Conor J. ; Hauser, Robert A. ; Hollander, David A.

ABSTRACT:

Background:

DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials.

Objective:

To report findings from PrevU, an early experience, real‐world observational program initiated following DAXI's FDA approval.

Methods:

Movement disorder specialists were provided with DAXI to treat CD patients per routine clinical practice, and were surveyed on dosing patterns and treatment intervals across the first three cycles of DAXI as doses were optimized.

Results:

A total of 234 CD patients (206 receiving BoNT treatment and 28 BoNT‐naïve) received a total of 589 DAXI treatments. Among patients with prior BoNT therapy, breakthrough symptoms within 12 weeks of prior BoNT therapy was the most common reason for patient selection (76.2%), and onabotulinumtoxinA was the most common prior toxin (68.4%). DAXI dose was titrated from a mean of 244.4 U (median 250 U) to 314.7 U (median 300 U) by Cycle 3. The ratio of DAXI dose to normalized prior BoNT dose was approximately 1.1:1 at initiation and 1.4:1 at Cycle 3. The mean (SD) time to re‐treatment across all DAXI cycles was 16.1 (5.6) weeks for all patients and 15.7 (4.5) weeks for patients with a history of breakthrough before 12 weeks with prior toxin. The most common adverse events were muscle weakness (2.4% of treatments), injection pain (1.4% of treatments), and dysphagia (0.3% of treatments).

Conclusions:

In this real‐world setting, DAXI demonstrated extended clinical benefit and a favorable safety profile.

01 Jun 2026·AESTHETIC PLASTIC SURGERY

Challenging Interchangeability: Dynamic Dose-Response Modelling of Botulinum Toxin A Products

Article

Author: Webb, William Richard ; Wu, Woffles T L ; Rao, Parinitha ; Rahman, Eqram ; Sayed, Karim ; Avelar, Rui ; Carruthers, Jean D A

INTRODUCTION:

Botulinum Neurotoxin type A (BoNT-A) formulations are used worldwide for both aesthetic and therapeutic indications, yet dose conversion between products remains based on empirical ratios that ignore pharmacodynamic variability. This study aimed to generate dynamic, time-resolved dose equivalence estimates for six FDA-approved BoNT-A formulations, onabotulinumtoxinA (ONA), abobotulinumtoxinA (ABO), incobotulinumtoxinA (INCO), daxibotulinumtoxinA (DAXI), prabotulinumtoxinA (PRABO), and letibotulinumtoxinA (LETI) and to assess how their clinical performance differs over time.

METHODS:

A hybrid, time-resolved in silico pharmacodynamic model was developed to simulate onset, peak effect, and decay kinetics using data aggregated from 49 clinical trials and regulatory submissions. Each formulation was modelled in 10,000 virtual patients to capture real-world variability in EC₅₀, maximal efficacy, and decay rate. Dose equivalence relative to 20 U of ONA was determined using two independent metrics: the area under the response curve (AURC) and time above a standardized efficacy threshold. External validation was performed against independent clinical datasets.

RESULTS:

Simulated durations ranged from 10.6 weeks (ABO) to 14.5 weeks (PRABO), matching published clinical means within ±1.2 weeks. Time-resolved conversion ratios revealed significant temporal drift: ABO increased from 2.0 to 2.7 (≈35% drift), LETI from 1.1 to 1.4 (≈27 %), while DAXI and PRABO demonstrated decreasing ratios (≈15% drift), reflecting superior persistence. Efficiency analysis ranked PRABO and DAXI highest (AURC/unit = 0.059 and 0.057), followed by ONA (0.050), INCO (0.040), LETI (0.035), and ABO (0.031). Global sensitivity analysis identified decay rate (koff) as the dominant determinant of efficacy duration (Sobol index = 0.52).

CONCLUSION:

Static dose conversion ratios fail to represent the dynamic pharmacodynamic behaviour of BoNT-A formulations. This simulation-based, data-driven approach reproduces clinical outcomes with high fidelity and provides a robust framework for effect-based dose equivalence, improving precision in product substitution and individualized treatment planning.

LEVEL OF EVIDENCE IV:

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

107

News (Medical) associated with Daxibotulinumtoixn A-LANM

01 Sep 2026

·allsci.com

Revelyx launches with recombinant botulinum toxin ready for Phase II readout

Nashville-based Revelyx Bio has launched as a clinical-stage company built around an exclusive license from China-based Chongqing Claruvis Pharmaceutical for YY003, a recombinant botulinum toxin type A (rBoNT/A) in a ready-to-use liquid formulation. Revelyx holds rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong, and Macau. Financial terms were not disclosed. YY003 is produced via recombinant expression in E. coli rather than conventional Clostridium botulinum fermentation, a manufacturing distinction Claruvis describes as offering greater control over neurotoxin identity and purity. The ready-to-use prefilled syringe format eliminates the reconstitution step required for currently approved leading botulinum toxin products. The US FDA cleared an investigational new drug application for YY003 in September 2024, and a Phase II study in adults with moderate-to-severe glabellar lines has been completed. Revelyx said it expects to report topline data in Q3 2026. Claruvis's platform credentials are anchored by Retoxin (YY001), a related lyophilized rBoNT/A that received approval from China's National Medical Products Administration in March 2026 — the first approved recombinant botulinum toxin type A anywhere in the world. YY003 is a distinct asset, differentiated from Retoxin primarily by its liquid formulation. Claruvis is separately advancing Retoxin in a Phase III trial in China for upper-limb spasticity secondary to stroke. The deal is Revelyx's founding transaction. The company is backed by NRL Capital, whose founding partner Xianghong Lin also founded BioBay, a major life sciences park in Suzhou. Dustin Sjuts, appointed CEO at launch, most recently served as president of Revance Therapeutics, where he oversaw the FDA approvals and US commercial launches of daxibotulinumtoxinA-lanm (Daxxify) for glabellar lines and cervical dystonia. The structure — a purpose-built Western company formed around a single-asset exclusive license from an Asian originator, with the originator retaining Greater China rights — resembles the model used by Evolus, which was built around an exclusive license from South Korea's Daewoong Pharmaceutical for prabotulinumtoxinA (Jeuveau) covering the US and Europe. In the botulinum toxin market, approved competitors — including onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and letibotulinumtoxinA (Letybo) — are all derived from bacterial fermentation and require reconstitution before injection. No rBoNT/A has been approved by the FDA. Revelyx has stated its goal is to deliver the first FDA-approved recombinant botulinum neurotoxin type A. Spot something wrong? Report an issue with this article

31 Aug 2026

·www.biospace.com

Revelyx Bio Launches to Advance YY003, an Investigational Recombinant Botulinum Toxin Type A in a Ready-to-Use Liquid Formulation

Company aims to deliver the first FDA-approved recombinant botulinum neurotoxin type A (rBoNT/A) Phase II study in moderate-to-severe glabellar lines completed; topline data expected in Q3 2026 Dustin Sjuts, former President of Revance Therapeutics, has been appointed Chief Executive Officer, bringing 20 years of biopharma leadership in commercial strategy and product launches NASHVILLE, Tenn., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Revelyx Bio, Inc., a clinical-stage biopharmaceutical company, today announced its launch following an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd., for YY003, a ready-to-use liquid formulation of recombinant botulinum toxin type A (rBoNT/A). Under the terms of agreement, Revelyx holds exclusive rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong and Macau. Additionally, the company announced the appointment of Dustin Sjuts as Chief Executive Officer and member of its Board of Directors. “Revelyx is focused on combining YY003’s differentiated science with a clear development path to bring next-generation recombinant innovation to an established, fast-growing market,” said Dustin Sjuts, Chief Executive Officer of Revelyx Bio. “We will advance our lead asset with disciplined execution across clinical development, regulatory strategy and CMC as we prepare to report topline Phase II results and position the program for late-stage development.” From Conventional Fermentation to Precision Genetic Engineering YY003 is an investigational rBoNT/A formulated as a ready-to-use liquid and presented in a prefilled syringe. Produced via recombinant expression in E. coli rather than traditional Clostridium botulinum culture purification, the manufacturing process offers precise control over neurotoxin identity and purity. The resulting protein is structurally identical to naturally derived neurotoxin, offering the potential for high specific activity and enhanced safety profile. Recombinant manufacturing is a proven, highly scalable platform used to produce biologic medicines for over 40 years. YY003 builds on Claruvis Pharmaceutical’s proprietary recombinant platform, which also underpins Retoxin® (YY001). In March 2026, Claruvis secured approval from China’s National Medical Products Administration (NMPA) for Retoxin® to temporarily improve moderate-to-severe glabellar lines in adults - marking the world’s first approved rBoNT/A. Retoxin® is currently commercially available in China, with pivotal Phase III data published in Aesthetic Surgery Journal . Claruvis is also advancing Retoxin® in a Phase III trial in China for adult upper-limb spasticity secondary to stroke. Phase II Study of YY003 in Moderate-to-Severe Glabellar Lines Completed The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug application for YY003 in September 2024. A randomized, double-blind, vehicle-controlled Phase II study of YY003 in adults with moderate-to-severe glabellar lines has been completed at clinical sites in Australia. Revelyx expects to report topline results in Q3 2026. “Having founded and led BioBAY, I have seen firsthand the quality and scale of innovation emerging from China’s biotechnology ecosystem,” said Xianghong Lin, Founding Partner of NRL Capital and original Founder of BioBay. “NRL incubated Revelyx to bring that innovation to global markets by pairing high-potential clinical programs with robust development, regulatory, CMC and commercial leadership required to advance them. YY003 is a compelling first example of this strategy, and Dustin brings the ideal operating experience and vision to lead it through the next stages of global growth.” Mr. Sjuts brings over 20 years of experience building and scaling public and private life sciences companies. Through his career, he has advanced biologics, specialty pharmaceuticals and medical technologies from clinical development through manufacturing and commercialization, with deep expertise in injectable therapies and neuromodulators. Most recently, Mr. Sjuts served as President of Revance Therapeutics, where he oversaw commercial, clinical, regulatory and technical operations. During his tenure, he led the FDA approvals and U.S. commercial launches of DAXXIFY® (daxibotulinumtoxinA-lanm) for moderate-to-severe glabellar lines and cervical dystonia in adults, as well as the U.S. commercial launch of the RHA® Collection of dermal fillers. Before becoming President, he served as the company’s Chief Commercial Officer. Earlier, Mr. Sjuts led Galderma’s aesthetics business in Greater China from Shanghai and held commercial leadership roles at Allergan. About Revelyx Bio Revelyx Bio, Inc. is a private, clinical-stage biopharmaceutical company developing and advancing differentiated therapies sourced from Asia-Pacific innovators for the United States and other global markets. The company combines selective in-licensing with expertise in clinical development, regulatory strategy, chemistry, manufacturing and controls (CMC), and commercialization. Its lead program, YY003, is an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation being developed for aesthetic and therapeutic indications. Revelyx holds exclusive rights to develop and commercialize YY003 in all territories outside mainland China, Hong Kong and Macau. Learn more at or connect with us on LinkedIn . About Claruvis Chongqing Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, is a biopharmaceutical company dedicated to developing recombinant botulinum toxin products for aesthetic and therapeutic indications. Claruvis developed Retoxin® (YY001), the world’s first approved recombinant botulinum toxin type A (rBoNT/A), and continues to advance a robust pipeline powered by its proprietary recombinant neurotoxin technology. For more information, visit MingMed Biotechnology at . Trademarks DAXXIFY® is a registered trademark of Revance Therapeutics, Inc. RHA® is a registered trademark of TEOXANE SA. Retoxin® is a registered trademark of Chongqing Claruvis Pharmaceutical Co., Ltd. Media Inquiries info@revelyx.com A photo accompanying this announcement is available here .

License out/inPhase 2Executive ChangePhase 3Drug Approval

18 Aug 2026

·www.fiercepharma.com

Revance hires Janelle Wichmann as chief marketing officer of skincare unit

Revance has appointed Ulta Beauty and Procter & Gamble alum Janelle Wichmann as its new chief marketing officer for skincare, as it looks to boost the commercial penetration of its Botox rival, Daxxify. Wichmann will lead the company's Skincare marketing strategy, brand development and commercial growth initiatives, according to a statement. She will also be in charge of strengthening innovation and overseeing efforts to “deepen engagement with consumers, healthcare professionals and strategic partners across channels,” as well as spearheading “consumer skincare digital, ecommerce and loyalty,” the release said. “Janelle joins Revance at an important moment in our evolution, bringing the vision and experience to elevate our Skincare brands while helping shape how we build brands across the enterprise," said CEO Nadeem Moiz. “Her appointment reflects a more connected leadership model that places marketing closer to our strategic decision-making and creates new opportunities to share consumer insights, creative thinking and commercial capabilities across Aesthetics and Skincare," he said in the company's announcement. "By uniting an expanded leadership team across divisions, we can unlock greater portfolio value and build category-leading brands.” Revance markets anti-wrinkle therapy Daxxify, a rival to AbbVie’s Botox, which won FDA approval in 2022. Both work as injected neuromodulators. Botox continues to dominate the space, with Botox Cosmetics generating $2.6 billion in sales in 2025. Evolus also sells its rival Jeuveau, which was approved by the FDA in 2019. Revance, which was bought out by Crown Labs for $924 million in 2024, no longer gives out sales numbers for its drug, but it had been making around $90 million a year before the merger turned it from a public to a private company. While its sales numbers are tiny in relation to its rival, what Revance hopes sets Daxxify apart is its reliance on peptide exchange technology. This gives Daxxify a staying-power edge over its AbbVie rival, the company contends. While Botox injections last for three months, Daxxify can sustain results for half a year and has worked for up to nine months in some patients, the company said at the time of its first approval. The drug also in 2023 snagged its second FDA green light to treat cervical dystonia in adults. Cervical dystonia causes the neck muscles to contract involuntarily, leading to abnormal movements, pain and awkward posture of the head and neck. The condition, for which Botox is considered a first-line treatment, affects roughly 60,000 people in the U.S. Both Evolus and Revance have gone after AbbVie in marketing pushes over the years as they look to chip away at Botox’s major market dominance. In 2023, Revance asked people to “Break Up With Botox,” while, in 2022, Evolus launched “Switch Your Tox and Love Evolus Forever,” which had an online and digital marketing focus and wanted consumers to move away from Botox and on to Jeuveau.

Drug ApprovalExecutive ChangeAcquisition

100 Deals associated with Daxibotulinumtoixn A-LANM

External Link

KEGG	Wiki	ATC	Drug Bank
D10921	-	M03AX01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dystonic Disorders	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	22 Nov 2024
cervical dystonia	United States	Revance Therapeutics, Inc.	11 Aug 2023
Glabellar frown lines	United States	Revance Therapeutics, Inc.	07 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Torticollis	NDA/BLA	United States	Revance Therapeutics, Inc.	20 Oct 2022
Isolated cervical dystonia	Phase 3	United States	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Austria	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Canada	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Czechia	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	France	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Germany	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Poland	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	Spain	Revance Therapeutics, Inc.	20 Jun 2018
Isolated cervical dystonia	Phase 3	United Kingdom	Revance Therapeutics, Inc.	20 Jun 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05158166 (CTgov)	Phase 1/2	Spastic Dysphonia	22	DaxibotulinumtoxinA	bmpymrdyjf(zggasfbexf) = tlytazdqer pnuxerkkiw (bdnsnceqid, 8.18) View more	-	27 Mar 2026
CTR20202553 (Pubmed)	-	Facial wrinkles	307	Daxxify	moezykrepj(tevnlocxco) = apmapjlubs uozwlspgez (hbzinmopkc ) View more	Positive	01 Dec 2024
				安慰剂	moezykrepj(tevnlocxco) = vnapngbnab uozwlspgez (hbzinmopkc )
ASPEN-1 (MDS2024)	Phase 3	cervical dystonia	321	DaxibotulinumtoxinA	ugntovtptl(nnrcknbxch) = keiwkvazff wyfvsbibxy (yfwijrwgit ) View more	Positive	27 Sep 2024
AAN2024	Not Applicable	cervical dystonia	-	DaxibotulinumtoxinA	nwbhteguxc(rthcpsighf) = wwcdumsgcs hksgfwqfes (iisexfaljj ) View more	-	09 Apr 2024
NCT02973269 (CTgov)	Phase 2	Fasciitis, Plantar	7	daxibotulinumtoxin type A (DAXI 240 U)	rnnoiqmrnq(qxtlckhwmd) = keloppeszx geastwvrjn (gmfozsknio, 11.0) View more	-	03 Apr 2024
				Placebo (Placebo)	rnnoiqmrnq(qxtlckhwmd) = tlcafouzwd geastwvrjn (gmfozsknio, 12.1) View more
NCT03608397 \| EUCTR2018-000446-19-AT (ASPEN-1, Pubmed \| Neurology) Manual	Phase 3	cervical dystonia	301	DAXI125U	wqupybivem(cypilssrzc) = dyfhlrqtfe eqogpazjdx (cmudhvkghe, 1.30) View more	Positive	31 Jan 2024
				DAXI250U	wqupybivem(cypilssrzc) = qdzcmsjean eqogpazjdx (cmudhvkghe, 1.25) View more
NCT03825315 (CTgov)	Phase 2	Fasciitis, Plantar	155	DAXI 80 U (DAXI 80 U)	wnpghvwhhv(yfkcfvzuau) = zplvnughho ovvbzlhjmy (novkqdnplm, 0.329) View more	-	21 Sep 2023
				DAXI 120 U (DAXI 120 U)	wnpghvwhhv(yfkcfvzuau) = jhgdoicure ovvbzlhjmy (novkqdnplm, 0.298) View more
NCT03821402 (JUNIPER, CTgov)	Phase 2	Stroke \| Limb spasticity \| Brain Injuries, Traumatic ... View more	83	DAXI (DAXI 250 U)	xovebtywjw(bjiowzxkid) = kghiwbdvpb slpdgqezmf (jamwpynhhx, 0.25) View more	-	21 Sep 2023
				DAXI (DAXI 375 U)	xovebtywjw(bjiowzxkid) = fbjsylnckz slpdgqezmf (jamwpynhhx, 0.26) View more
NCT03608397 (FDA) Manual	Phase 3	cervical dystonia	301	Placebo	csqcthhgvy(gvfygfnuom) = bikcymolli tkdtcfnkrv (qvsntoheam )	Positive	11 Aug 2023
				DAXI 125 U	csqcthhgvy(gvfygfnuom) = ecdakmxhmf tkdtcfnkrv (qvsntoheam )
GL-2 (FDA) Manual	Not Applicable	Glabellar frown lines	609	DAXXIFY (STUDY GL-1)	jhehqqisyx(hmksovgmkx) = zslhxatfyc dmfkruwgto (kfjivxscmd ) View more	Positive	11 Aug 2023
				Placebo (STUDY GL-1)	jhehqqisyx(hmksovgmkx) = prrncebfre dmfkruwgto (kfjivxscmd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis